- 関
- transforming growth factor beta receptor
WordNet
- to remain unmolested, undisturbed, or uninterrupted -- used only in infinitive form; "let her be"
- work in a specific place, with a specific subject, or in a specific function; "He is a herpetologist"; "She is our resident philosopher" (同)follow
- have life, be alive; "Our great leader is no more"; "My grandfather lived until the end of war" (同)live
- be identical to; be someone or something; "The president of the company is John Smith"; "This is my house"
- happen, occur, take place; "I lost my wallet; this was during the visit to my parents house"; "There were two hundred people at his funeral"; "There was a lot of noise in the kitchen"
- have the quality of being; (copula, used with an adjective or a predicate noun); "John is rich"; "This is not a good answer"
- occupy a certain position or area; be somewhere; "Where is my umbrella?" "The toolshed is in the back"; "What is behind this behavior?"
- spend or use time; "I may be an hour"
- stake on the outcome of an issue; "I bet $100 on that new horse"; "She played all her money on the dark horse" (同)wager, play
- the act of gambling; "he did it on a bet" (同)wager
- maintain with or as if with a bet; "I bet she will be there!" (同)wager
- second in order of importance; "the candidate, considered a beta male, was perceived to be unable to lead his party to victory"
- the 2nd letter of the Greek alphabet
- preliminary or testing stage of a software or hardware product; "a beta version"; "beta software"
- receptors postulated to exist on nerve cell membranes of the sympathetic nervous system in order to explain the specificity of certain agents that affect only some sympathetic activities (such as vasodilation and increased heart beat) (同)beta-adrenergic_receptor, beta-adrenoceptor
PrepTutorEJDIC
- 《連結語として補語を伴なって…『である』,…だ,…です / 《位置・場所を表す語句を伴って》(…に)『ある』,いる(occupy a place or situation) / 〈物事が〉『存在する』,ある(exist);〈生物が〉生存する,生きている(live) / 行われる,起こる,発生する(take place, occur) / 存続する,そのままでいる(remain as before) / 《『be to』 do》 / …する予定である,…することになっている / …すべきだ / 《受動態の不定詞を伴って》…できる / 《命令》…するのだ / 《条件節に》…する意図がある / 《『if…were to』 do》…するとしたなら / 《『be』 do『ing』》《進行形》 / 《進行中の動作》…している,しつつある / 《近い未来》…しようとしている,するつもり / 《動作の反復》(いつも)…している / 《『be』+『他動詞の過去分詞』》《受動態》…される,されている / 《『be』+『自動詞の過去分詞』》《完了形》…した[状態にある]
- 『かけ』・(…との)かけ《+『with』+『名』》 / かけた物(金) / かけの対象 / 〈金・物〉'を'『かける』 / (かけ事・ゲームなどで)〈人〉‘と'『かけをする』《+『名』〈人〉+『on』+『名』》 / (…に)『かける』《+『on』(『against』)+『名』(one's do『ing』)》
- ベータ(ギリシア語アルファベットの第2文字;B,β;英語のB,b に遭当)
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/06/17 05:40:18」(JST)
[Wiki en表示]
| transforming growth factor beta, receptor type I (activin A receptor type II-like kinase, 53kDa) |
| Identifiers |
| Symbol |
TGFBR1 |
| Alt. symbols |
ALK5 |
| Entrez |
7046 |
| HUGO |
11772 |
| OMIM |
190181 |
| RefSeq |
NM_004612 |
| UniProt |
P36897 |
| Other data |
| Locus |
Chr. 9 q22 |
| transforming growth factor beta, receptor type II (70/80kDa) |
| Identifiers |
| Symbol |
TGFBR2 |
| Alt. symbols |
MFS2 |
| Entrez |
7048 |
| HUGO |
11773 |
| OMIM |
190182 |
| RefSeq |
NM_001024847 |
| UniProt |
P37173 |
| Other data |
| Locus |
Chr. 3 p22 |
| transforming growth factor beta, receptor type III |
| Identifiers |
| Symbol |
TGFBR3 |
| Alt. symbols |
β-Glycan |
| Entrez |
7049 |
| HUGO |
11774 |
| OMIM |
600742 |
| RefSeq |
NM_003243 |
| UniProt |
Q03167 |
| Other data |
| Locus |
Chr. 1 p33-p32 |
Not to be confused with TGFβ superfamily receptor.
Transforming growth factor beta (TGFβ) receptors are single pass serine/threonine kinase receptors. They exist in several different isoforms that can be homo- or heterodimeric.[1] The number of characterized ligands in the TGFβ superfamily far exceeds the number of known receptors, suggesting the promiscuity that exists between the ligand and receptor interactions.
TGFβ is a growth factor and cytokine involved in paracrine signalling and can be found in many different tissue types, including brain, heart, kidney, liver, and testes. Over-expression of TGFβ can induce renal fibrosis, causing kidney disease, as well as diabetes, and ultimately end-stage renal disease. Recent developments have found that, using certain types of protein antagonists against TGFβ receptors, can halt and in some cases reverse the effects of renal fibrosis.
Three TGFβ superfamily receptors specific for TGFβ, the TGFβ receptors, can be distinguished by their structural and functional properties. TGFβR1 (ALK5) and TGFβR2 have similar ligand-binding affinities and can be distinguished from each other only by peptide mapping. Both TGFβR1 and TGFβR2 have a high affinity for TGFβ1 and low affinity for TGFβ2. TGFβR3 (β-glycan) has a high affinity for both homodimeric TGFβ1 and TGFβ2 and in addition the heterodimer TGF-β1.2.[2] The TGFβ receptors also bind TGFβ3.
See also
- TGFβ superfamily receptor
- TGFβ signaling pathway
- TGFβ superfamily
References
- ^ Doré JJ, Edens M, Garamszegi N, Leof EB (November 1998). "Heteromeric and homomeric transforming growth factor-beta receptors show distinct signaling and endocytic responses in epithelial cells". The Journal of Biological Chemistry. 273 (48): 31770–7. PMID 9822641. doi:10.1074/jbc.273.48.31770. (free full text)
- ^ Cheifetz S, Andres JL, Massagué J (November 1988). "The transforming growth factor-beta receptor type III is a membrane proteoglycan. Domain structure of the receptor". The Journal of Biological Chemistry. 263 (32): 16984–91. PMID 2903157.
External links
- TGF-beta Receptors at the US National Library of Medicine Medical Subject Headings (MeSH)
|
Cell signaling: TGFβ signaling pathway
|
| TGF beta superfamily of ligands |
|
TGF beta family
|
|
|
Bone morphogenetic proteins
|
- BMP2
- BMP3
- BMP4
- BMP5
- BMP6
- BMP7
- BMP8a
- BMP8b
- BMP10
- BMP15
|
|
Growth differentiation factors
|
- GDF1
- GDF2
- GDF3
- GDF5
- GDF6
- GDF7
- Myostatin/GDF8
- GDF9
- GDF10
- GDF11
- GDF15
|
|
Other
|
- Activin and inhibin
- Anti-müllerian hormone
- Nodal
|
|
TGF beta receptors
(Activin, BMP) |
|
TGFBR1:
|
- Activin type 1 receptors
- ACVRL1
- BMPR1
|
|
TGFBR2:
|
- Activin type 2 receptors
- AMHR2
- BMPR2
|
|
TGFBR3:
|
|
|
| Transducers/SMAD |
- R-SMAD (SMAD1
- SMAD2
- SMAD3
- SMAD5
- SMAD9)
- I-SMAD (SMAD6
- SMAD7)
- SMAD4
|
| Ligand inhibitors |
- Cerberus
- Chordin
- Decorin
- Follistatin
- Gremlin
- Lefty
- LTBP1
- Noggin
- PARN
- THBS1
|
| Coreceptors |
|
| Other |
|
|
Receptors: growth factor receptors
|
| Type I cytokine receptor |
- Nerve growth factors: Ciliary neurotrophic factor
- Erythropoietin
|
| Receptor protein serine/threonine kinase |
- TGF pathway: TGF-beta
- Activin
- Bone morphogenetic protein
|
| Receptor tyrosine kinase |
|
|
- Nerve growth factors: high affinity Trk
|
|
|
- Somatomedin
- Insulin-like growth factor 1
|
- ErbB/Epidermal growth factor
|
|
|
|
| Tumor necrosis factor receptor |
- Nerve growth factors: Low affinity/p75
|
| Ig superfamily |
- Platelet-derived growth factor
- Stem cell factor
|
| Other/ungrouped |
- Somatomedin
- Insulin-like growth factor 2
|
|
Cytokine receptors
|
Chemokine receptor
(GPCRs) |
| CC |
- CCR1 / CCRL1
- CCR2
- CCRL2
- CCR3
- CCR4
- CCR5
- CCR6
- CCR7
- CCR8
- CCR9
- CCR10
|
| CXC |
- IL-8
- CXCR3
- CXCR4
- CXCR5
- CXCR6
- CXCR7
|
| Other |
|
|
| TNF receptor |
| 1-10 |
- TNFR1 (TNFRSF1A)
- TNFR2 (TNFRSF1B)
- LTBR (TNFRSF3)
- CD134 (TNFRSF4)
- CD40 (TNFRSF5)
- Fas receptor (TNFRSF6)
- DcR3 (TNFRSF6B)
- CD27 (TNFRSF7)
- CD30 (TNFRSF8)
- CD137 (TNFRSF9)
|
| 11-20 |
- DR4 (TNFRSF10A)
- DR5 (TNFRSF10B)
- DcR1 (TNFRSF10C)
- DcR2 (TNFRSF10D)
- RANK (TNFRSF11A)
- Osteoprotegerin (TNFRSF11B)
- TweakR (TNFRSF12A)
- TACI (TNFRSF13B)
- BAFFR (TNFRSF13C)
- HVEM (TNFRSF14)
- NGFR (TNFRSF16)
- BCMA (TNFRSF17)
- GITR (TNFRSF18)
- TAJ/TROY (TNFRSF19)
|
| 21-27 |
- DR6 (TNFRSF21)
- DR3 (TNFRSF25)
- EDA2R (TNFRSF27)
|
|
| JAK-STAT |
| Type I |
| γ-chain |
- Interleukin receptors
- IL2R / IL2RA/IL2RB / IL15R
- IL4R / IL13R / IL13RA1 / IL13RA2
- IL7R / IL7RA
- IL9R
- IL21R
|
| β-chain |
- Interleukin receptors
- IL3R / IL3RA
- IL5R / IL5RA
- GM-CSF
|
| gp130 |
- Interleukin receptors
- IL6RA
- 11/IL11RA
- 27/IL27RA
- OSMR
- LIFR
- CNTFR
|
| IL12RB1 |
- Interleukin receptors
- IL12R/IL12RB1/IL12RB2
- IL23R23
|
| Other |
- hormone receptor: GH
- prolactin
|
|
| Type II |
- Interleukin receptors
- IL10R / IL10RA / IL10RB / IL22R / IL22RA1 / IL22RA2
- IL20R / IL20RA / IL20RB
- IL28R
- Interferon receptors
- -α/β / IFNAR1/IFNAR2
- -γ/IFNGR1 / IFNGR2
|
|
| Ig superfamily |
- CSF1
- KIT
- IL1
- IL18R / IL18R1
|
| IL 17 family |
- IL17
- IL17RA
- IL17RB
- IL17RC
- IL17RD
- IL17RE
|
| S/T |
|
|
Kinases: Serine/threonine-specific protein kinases (EC 2.7.11-12)
|
|
Serine/threonine-specific protein kinases (EC 2.7.11.1-EC 2.7.11.20)
|
|
|
|
|
Serine/threonine-specific protein kinases (EC 2.7.11.21-EC 2.7.11.30)
|
| Polo kinase (EC 2.7.11.21) |
|
| Cyclin-dependent kinase (EC 2.7.11.22) |
- CDK1
- CDK2
- CDKL2
- CDK3
- CDK4
- CDK5
- CDKL5
- CDK6
- CDK7
- CDK8
- CDK9
- CDK10
- CDK12
- CDC2L5
- PCTK1
- PCTK2
- PCTK3
- PFTK1
- CDC2L1
|
| (RNA-polymerase)-subunit kinase (EC 2.7.11.23) |
- RPS6KA5
- RPS6KA4
- P70S6 kinase
- P70-S6 Kinase 1
- RPS6KB2
- RPS6KA2
- RPS6KA3
- RPS6KA1
- RPS6KC1
|
| Mitogen-activated protein kinase (EC 2.7.11.24) |
- Extracellular signal-regulated
- MAPK1
- MAPK3
- MAPK4
- MAPK6
- MAPK7
- MAPK12
- MAPK15
- C-Jun N-terminal
- P38 mitogen-activated protein
|
| MAP3K (EC 2.7.11.25) |
- MAP kinase kinase kinases
- MAP3K1
- MAP3K2
- MAP3K3
- MAP3K4
- MAP3K5
- MAP3K6
- MAP3K7
- MAP3K8
- RAFs
- MLKs
- MAP3K12
- MAP3K13
- MAP3K9
- MAP3K10
- MAP3K11
- MAP3K7
- ZAK
- CDC7
- MAP3K14
|
| Tau-protein kinase (EC 2.7.11.26) |
|
| (acetyl-CoA carboxylase) kinase (EC 2.7.11.27) |
|
| Tropomyosin kinase (EC 2.7.11.28) |
|
| Low-density-lipoprotein receptor kinase (EC 2.7.11.29) |
|
| Receptor protein serine/threonine kinase (EC 2.7.11.30) |
- Bone morphogenetic protein receptors
- BMPR1
- BMPR1A
- BMPR1B
- BMPR2
- ACVR1
- ACVR1B
- ACVR1C
- ACVR2A
- ACVR2B
- ACVRL1
- Anti-Müllerian hormone receptor
|
|
|
|
Dual-specificity kinases (EC 2.7.12)
|
| MAP2K |
- MAP2K1
- MAP2K2
- MAP2K3
- MAP2K4
- MAP2K5
- MAP2K6
- MAP2K7
|
|
|
|
TGFβ receptor superfamily modulators
|
| Type I |
|
ALK1 (ACVRL1)
|
- Agonists: Activin (A, B, AB)
- Avotermin
- BMP (10)
- Cetermin
- GDF (2 (BMP9))
- TGFβ (1, 2, 3)
- Antibodies: Ascrinvacumab
- Kinase inhibitors: K-02288
- ML-347 (LDN-193719, VU0469381)
- Decoy receptors: Dalantercept
- Other inhibitors: Disitertide
|
|
ALK2 (ACVR1A)
|
- Agonists: Activin (A, B, AB)
- AMH (MIS)
- Avotermin
- BMP (5, 6, 7, 8A, 8B)
- Eptotermin alfa
- TGFβ (1, 2, 3)
- Kinase inhibitors: DMH-1
- DMH-2
- Dorsomorphin (BML-275)
- K-02288
- ML-347 (LDN-193719, VU0469381)
|
|
ALK3 (BMPR1A)
|
- Agonists: AMH (MIS)
- BMP (2, 4, 5, 6, 7, 8A, 8B)
- Dibotermin alfa
- Eptotermin alfa
- Kinase inhibitors: DMH-2
- Dorsomorphin (BML-275)
- K-02288
|
|
ALK4 (ACVR1B)
|
- Agonists: Activin (A, B, AB)
- GDF (1, 3, 11 (BMP11))
- Myostatin (GDF8)
- Nodal
- Antagonists: Inhibin (A, B)
- Lefty (1, 2)
- Kinase inhibitors: A 83-01
- SB-431542
- SB-505124
|
|
ALK5 (TGFβR1)
|
- Agonists: Avotermin
- GDF (10 (BMP3B), 11 (BMP11))
- TGFβ (1, 2, 3)
- Antibodies: Fresolimumab
- Lerdelimumab
- Metelimumab
- Kinase inhibitors: A 83-01
- D-4476
- GW-788388
- LY-364947
- LY-2109761
- Galunisertib (LY-2157299)
- R-268712
- RepSox (E-616452, SJN-2511)
- SB-431542
- SB-505124
- SB-525334
- SD-208
|
|
ALK6 (BMPR1B)
|
- Agonists: BMP (2, 4, 5, 6, 7, 8A, 8B, 15 (GDF9B))
- Dibotermin alfa
- Eptotermin alfa
- GDF (5 (BMP14), 6 (BMP13), 7 (BMP12), 9, 15)
- Radotermin
- Kinase inhibitors: DMH-2
- Dorsomorphin (BML-275)
- K-02288
|
|
ALK7 (ACVR1C)
|
- Agonists: GDF (1, 3, 11 (BMP11))
- Nodal
- Antagonists: Lefty (1, 2)
- Kinase inhibitors: A 83-01
- SB-431542
- SB-505124
|
|
| Type II |
|
TGFβR2
|
- Agonists: Avotermin
- GDF (10 (BMP3B))
- TGFβ (1, 2, 3)
- Antibodies: Fresolimumab
- Lerdelimumab
- Metelimumab
- Kinase inhibitors: DMH-2
- LY-364947
|
|
BMPR2
|
- Agonists: BMP (2, 4, 6, 7, 10)
- Dibotermin alfa
- Eptotermin alfa
- GDF (2 (BMP9), 5 (BMP14), 6 (BMP13), 7 (BMP12))
- Radotermin
- Antagonists: Inhibin (A, B)
|
|
ACVR2A (ACVR2)
|
- Agonists: Activin (A, B, AB)
- BMP (2, 4, 5, 6, 7, 8A, 8B, 15 (GDF9B))
- Dibotermin alfa
- Eptotermin alfa
- GDF (1, 3, 5 (BMP14), 6 (BMP13), 7 (BMP12), 9, 11 (BMP11), 15)
- Myostatin (GDF8)
- Nodal
- Radotermin
- Antagonists: Inhibin (A, B)
- Lefty (1, 2)
- Decoy receptors: Sotatercept
|
|
ACVR2B
|
- Agonists: Activin (A, B, AB)
- BMP (2, 4, 6, 7)
- Dibotermin alfa
- Eptotermin alfa
- GDF (1, 3, 5 (BMP14), 6 (BMP13), 7 (BMP12))
- Myostatin (GDF8)
- Nodal
- Osteogenin (BMP3, BMP3A)
- Radotermin
- Antagonists: Inhibin (A, B)
- Lefty (1, 2)
- Decoy receptors: Ramatercept
|
|
AMHR2 (AMHR)
|
|
|
| Type III |
|
TGFβR3 (β-glycan)
|
- Ligands: Avotermin
- Inhibin (A, B)
- TGFβ (1, 2, 3)
|
|
| Unsorted |
- Endogenous antagonists/inhibitors: BAMBI
- Cerberus (CER1)
- Chordin
- DAN (PARN)
- Decorin
- Follistatin
- Gremlin (Drm)
- LTBP1
- Noggin
- TGIF
- Thrombospondin 1 (THBS1)
- Tomoregulin 1
- Antibodies: Stamulumab (against myostatin)
- TRC105 (against endoglin)
|
- See also: Receptor/signaling modulators
- Signaling peptide/protein receptor modulators
- Growth factor receptor modulators
- Cytokine receptor modulators
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Retinal pigment epithelium-derived transforming growth factor-β2 inhibits the angiogenic response of endothelial cells by decreasing vascular endothelial growth factor receptor-2 expression.
- Jeong HS1,2, Yun JH1, Lee DH1,2, Lee EH3, Cho CH1,2,4.
- Journal of cellular physiology.J Cell Physiol.2019 Apr;234(4):3837-3849. doi: 10.1002/jcp.27156. Epub 2018 Sep 7.
- PMID 30256387
- Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
- Mateus PAM1, Kido LA1,2, Silva RS1, Cagnon VHA1, Montico F1,3.
- The Prostate.Prostate.2019 Apr;79(5):515-535. doi: 10.1002/pros.23758. Epub 2018 Dec 25.
- PMID 30585351
- Extracellular matrix (ECM) stiffness and degradation as cancer drivers.
- Najafi M1, Farhood B2, Mortezaee K3.
- Journal of cellular biochemistry.J Cell Biochem.2019 Mar;120(3):2782-2790. doi: 10.1002/jcb.27681. Epub 2018 Oct 15.
- PMID 30321449
Japanese Journal
- Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis : a randomized controlled trial
- HIDAKA Hisashi,NAKAZAWA Takahide,SHIBUYA Akitaka,MINAMINO Tsutomu,TAKADA Juichi,TANAKA Yoshiaki,OKUWAKI Yusuke,WATANABE Masaaki,KOIZUMI Wasaburo
- Journal of gastroenterology 46(11), 1316-1323, 2011-11-01
- NAID 10030294951
- TGF-β1 System in Leydig Cells. Part I : Effect of hCG and Progesterone
- GONZALEZ Candela R.,GONZALEZ Betina,RULLI Susana B.,HUHTANIEMI Ilpo,CALANDRA Ricardo S.,GONZALEZ-CALVAR Silvia I.
- The Journal of reproduction and development 56(4), 389-395, 2010-08-01
- … Transforming growth factor beta 1 (TGF-β1) modulates male reproductive function. …
- NAID 10026621527
Related Links
- Function [edit] The protein encoded by this gene forms a heteromeric complex with type II TGF-beta receptors when bound to TGF-beta, transducing the TGF-beta signal from the cell surface to the cytoplasm. The encoded protein is a ...
- TGF-beta receptor 製品一覧 感度 分子量 (kDa) 抗体の由来 貯法 内在性 52 Rabbit-20 種交差性 (社内試験済) 交差する可能性がある種 社内試験はしていませんが、配列が100%相同であるため反応すると推定される種 ヒト、ラット ブタ ...
★リンクテーブル★
[★]
- 英
- TGF-beta receptor
- 関
- トランスフォーミング増殖因子β受容体、TGF-β受容体、TGF-βレセプター、TGFβレセプター
[★]
- 英
- TGF-beta receptor
- 関
- TGFβ受容体、トランスフォーミング増殖因子β受容体、TGF-βレセプター、TGFβレセプター
[★]
- 関
- TGF-beta receptor、TGFBR
[★]
- 英
- TGF-beta receptor
- 関
- TGFβ受容体、TGF-β受容体、TGF-βレセプター
[★]
- 英
- TGF-beta receptor
- 関
- TGFβ受容体、TGF-β受容体、TGFβレセプター
[★]
- 英
- transforming growth factor
- 同
- トランスフォーミング成長因子、トランスフォーミング増殖因子、形質転換増殖因子、形質転換成長因子
- 関
- TGF-β, transforming growth factor β
TGF
- TGF-β1、TGF-β2、TGF-β3、TGF-β4、TGF-β5
[★]
[★]
[★]
β、ベータ
[★]